Last reviewed · How we verify

NCT05851352

anti_endometrial Antibodies in Endometriosis

Status unknown Last updated 9 May 2023
What this trial tests

trial testing serum anti-endometrial antibodies in Anti-endometrial Antibodies in 30 participants. Status unknown.

Timeline
1 December 2020
Primary endpoint
1 June 2023
1 July 2023

Quick facts

Lead sponsorSouth Valley University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 December 2020
Primary completion1 June 2023
Estimated completion1 July 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

South Valley University

Who can join

Adults 15 to 35, female only, with Anti-endometrial Antibodies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this study is to asses the predictive value of serum anti\_endometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other South Valley University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05851352.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing